MORAb-004: Phase II started

Eisai's Morphotek Inc. subsidiary began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 8 mg/kg IV MORAb-004 once weekly plus best supportive care in up to 160 patients with refra...